Actively Recruiting

Age: 18Years +
MALE
NCT07077239

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity

Led by Jonsson Comprehensive Cancer Center · Updated on 2025-07-24

200

Participants Needed

1

Research Sites

576 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

Single-arm, prospective registry study assessing changes in acute patient-reported urinary (GU) and gastrointestinal (GI) quality of life at the 24-month post-treatment time point following magnetic resonance imaging (MRI)-guided or computed tomography (CT)-guided stereotactic body radiotherapy (SBRT) delivered to the prostate bed +/- pelvic lymph nodes. The decision to offer an adaptive treatment will be at the clinician's discretion.

CONDITIONS

Official Title

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity

Who Can Participate

Age: 18Years +
MALE

Eligibility Criteria

Eligible

You may qualify if you...

  • Histologically confirmed localized adenocarcinoma of the prostate treated with radical prostatectomy
  • Presence of at least one: adverse pathological features at prostatectomy, rising prostate-specific antigen on two or more tests exceeding 0.03 ng/mL, intermediate- or high-risk genomic classifier score, or prostate cancer in one or more lymph nodes at prostatectomy
  • CT scan and MRI of the pelvis within 120 days before enrollment (exceptions allowed for certain conditions)
  • Bone scan or advanced nuclear imaging within 120 days before enrollment if prostate-specific antigen is above 1.0 ng/mL
  • Age 18 years or older
  • Karnofsky Performance Status of 70 or higher and/or ECOG performance status less than 2
  • Ability to understand and willingness to sign informed consent
Not Eligible

You will not qualify if you...

  • Evidence of distant metastases (lymphadenopathy below the renal arteries may be considered local-regional)
  • Diagnosis of neuroendocrine or small cell carcinoma of the prostate
  • Prior pelvic radiotherapy
  • History of Crohn's Disease, Ulcerative Colitis, or Ataxia Telangiectasia

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 1 location

1

University of California at Los Angeles

Los Angeles, California, United States, 90095

Actively Recruiting

Loading map...

Research Team

C

CHRISTY PALODICHUK

CONTACT

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Prostate Cancer Postoperative Stereotactic Body Radiotherapy With Adaptive Technology for Minimizing Toxicity | DecenTrialz